Transcode Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 10
- Market Cap
- -
- Introduction
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Newton, MA.
Clinical Trials
2
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Study of TTX-MC138 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2024-02-15
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- TransCode Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT06260774
- Locations
- 🇺🇸
Mary Crowley Cancer Center, Dallas, Texas, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸START Mountain Region, West Valley City, Utah, United States
A Microdose Study of TTX-MC138-NODAGA-Cu64 in Subjects With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumor
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- TransCode Therapeutics
- Target Recruit Count
- 1
- Registration Number
- NCT05908773
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
News
CRISPR-Cas9 Market Set to Surge: Over 25 Therapies in Clinical Trials Expected to Launch Within 5-7 Years
The global CRISPR-Cas9 therapy market is rapidly expanding with over 25 therapies currently in clinical trials, many of which are expected to receive regulatory approval and enter the market within the next 5-7 years.
TransCode Therapeutics Secures $10 Million Funding to Advance RNA Cancer Therapy Clinical Trials
TransCode Therapeutics has raised $10 million through a registered direct offering of common stock and warrants, with proceeds directed toward advancing its lead RNA therapeutic candidate TTX-MC138 into clinical trials.
TransCode Therapeutics Completes Cohort 3 Dosing in Phase 1 Trial of TTX-MC138 for Metastatic Cancers
TransCode Therapeutics has completed initial dosing of all three patients in Cohort 3 of its Phase 1 clinical trial with TTX-MC138.
TransCode Therapeutics Advances Metastatic Cancer Therapy with TTX-MC138 Phase 1 Trial
TransCode Therapeutics has dosed the first two patients in a Phase 1 clinical trial of TTX-MC138, a novel therapy for metastatic cancers.